TD Cowen analyst Daniel Brennan has maintained their bullish stance on SOPH stock, giving a Buy rating on March 4.
Daniel Brennan has given his Buy rating due to a combination of factors including SOPHiA GENETICS’s solid financial performance and strategic positioning. The company reported a 4Q revenue of $17.7 million, which aligns with market expectations and slightly surpasses internal forecasts, indicating stable growth. Additionally, SOPHiA GENETICS has demonstrated strong operational discipline with a reduction in adjusted operating losses year-over-year, and management’s confidence in overcoming 2024’s headwinds further supports a positive outlook.
Another key factor in Brennan’s rating is the company’s robust business model and potential for long-term growth. SOPHiA GENETICS operates in a large, under-penetrated market and has a significant number of new customers poised to contribute to future revenue. The company’s solid balance sheet, with $80.2 million in cash, provides a strong financial foundation to support its growth initiatives. These elements collectively underpin Brennan’s optimistic view on the stock’s potential performance.